edward report second-quart revenu million underli
street estim million million respect beat
larg driven global tavr sale million came well expect
million result suggest meaning acceler underli growth
manag attribut quarter better-than-expect market demand notabl
follow weaker-than-expect first quarter broad-bas strength high-
low-volum center acceler demand europ fundament appear strong
price market share remain rel stabl
follow result manag guid toward top end prior rang
impli perform second half similar quarter though
move dynamicsand up-and-down start year add complexityw
believ growth acceler cours year follow fda approv
low-risk patient expect third quarter latter combin sever
product launch provid steadi stream catalyst next sever year
tmtt sale million came line million estim edward continu
ramp product cardioband benefit success launch pascal
eu quarter second-quart savr sale also came ahead estim
compani expand global roll-out inspira led strong adopt resili
follow strong quarter manag rais low end full year sale
guidanc billion billion underli growth near top
prior rang first half total underli compani growth
come like benefit anticip low-risk reimburs
approv second half well sever new product launch like sapien
ultra pascal believ guidanc conserv
edward report adjust ep street estim
respect benefit product effici favor tax rate
manag increas full year ep guidanc rang
previou guidanc
return equiti ttm
edward global leader treatment advanc cardiovascular diseas busi divid three
differ segment transcathet heart valv surgic heart valv critic care
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
conclus stock thought
overal second-quart result expect continu believ sale acceler throughout year
edward benefit new product launch secur reimburs low-risk patient popul believ
market demand build low-risk also high- intermediate-risk patient recent survey work
support use tavr patient multipl societi call surgic risk score longer guid choic
tavr versu savr like approv low-risk patient indic second half materi
catalyst volum next two-plu year remain enthusiast potenti market edward
durabl market share posit share trade hour time new adjust ep target believ
underli market dynam remain posit support continu double-digit growth market edward
posit global leader rate stock outperform
tavr underli growth mark acceler last quarter manag
expect tavr sale came well street manag expect quarter market demand acceler
back result present march though edward estim maintain market share saw
chang price demand seem driven increas public around tavr gener accept
clinician patient commun less invas techniqu still manag believ
borderlin increas patient low-risk categori compani still wait fda reimburs approv
later year would seem impli acceler sale approv gain though updat commentari
remain conserv given move piec includ potenti chang season new competit
horizon boston scientif though may flow-through demand follow weaker first
quarter believ fundament signal first quarter year-to-d encourag view guidanc
conserv note year-to-d growth still came similar guidanc high end rang
full year
believ growth acceler throughout year compani continu see benefit follow overwhelmingli
posit low-risk data present mid-march launch next-gener sapien ultra potenti see
impact nation coverag determin ncd publish june still bake much contribut
catalyst
 tavr second quarter grew high doubl digit versu low doubl digit first quarter larg
line market support growth high- low-volum center believ manag remain
conserv updat guidanc like still minim impact low-risk near term
wait fda approv reimburs still result quarter support thesi strength data
support increas util intermediate-risk popul addit modest low-risk creep recal
sapien achiev statist superior surgeon treatment arm composit primari endpoint one
manag assum potenti impact fda approv lotu edg expect impact may
minim devic like initi move control commerci launch approv use
high-risk patient model modest price headwind edward domest though may prove
grew midteen outsid unit statesin line market growthsuggest
acceler low-double-digit market rate estim last quarter regard launch sapien ultra
centera result larg posit review sapien ultra support grow util yet
manag decid discontinu self-expand centera valv taken increas proctor
train though repres modest headwind potenti result believ market acceler adopt
tavr larger impact compani note cardio poll post europcr
poll suggest tavr first-lin treatment patient isol sever aortic stenosi
regardless risk score primari reason answer cite valv durabl though
constraint compani need work outsid unit state result indic strong
demand tavr
tmtt revenu million line estim manag reiter guidanc million full
year sale segment continu benefit roll-out pascal europ though edward reiter focu
rel control launch focus procedur train clinic outcom ensur sustain growth
still manag highlight strong demand support recent present clasp studi show substanti
reduct mitral regurgit mr improv function endpoint like qualiti life treat
patient signific mr pascal system regard cardioband manag suggest product
continu improv suppli constraint progress lessen throughout second half
oper result review adjust gross margin basi point expect favor
product fx mix off-set continu invest compani global suppli chain edward deliv ep
come high end guidanc rang believ compani focus
appropri initi support margin expans long term continu double-digit ep growth
manag increas lower end full year sale guidanc rang billion previous billion
billion expect underli growth high end previou rang full-year adjust ep
guidanc increas rang previous full-year sale guidanc assum
increas tavr sale expect rang billion billion approxim
underli basi prior guidanc billion billion
reiter savr sale rang million million underli basi
guid high end prior critic care sale rang million million
reiter tmtt sale approxim million weight second half year cardioband manufactur
scale pascal gain momentum
third quarter sale expect rang billion billion adjust ep expect
summari model updat
newpreviouschang newpreviouschang millioncrit milliontot billiony/i growth margin margin incom margin lifesci ew summari chang modelthird quarter guidancefull-year import disclosur
